论文部分内容阅读
目的探讨欣母沛治疗宫缩乏力性产后出血患者的临床疗效。方法选取2014年1月至2016年6月于我院治疗的宫缩乏力性产后出血产妇共60人,其中欣母沛治疗组患者30人,缩宫素治疗组患者30人,观察两组患者德邦治疗效果及用药安全性。结果 (1)欣母沛治疗组患者的治疗后的平均出血量及平均出血时间明显短于缩宫素治疗组患者,两者比较,差异显著,P<0.05。(2)欣母沛组患者治疗有效28人,治疗无效2人,缩宫素组患者治疗有效20人,治疗无效10,两者比较,差异显著,P<0.05。结论将欣母沛用于宫缩乏力性产后出血患者的治疗中,可在短时间内显著提高患者宫缩力度,减少患者出血量,疗效显著,是挽救宫缩乏力性出血产妇生命的不二选择。
Objective To investigate the clinical efficacy of Xinmaopen in the treatment of uterine inertia postpartum hemorrhage. Methods A total of 60 pregnant women with uterine inertia postpartum hemorrhage were treated in our hospital from January 2014 to June 2016. Among them, 30 were treated with Xinmapei and 30 were treated with oxytocin. Debon treatment effect and medication safety. Results (1) The average amount of bleeding and the average bleeding time after treatment in the Xinmaitai treatment group were significantly shorter than those in the oxytocin treatment group, the difference was significant (P <0.05). (2) 28 patients in Xinmaopen group were treated effectively, 2 were ineffective, 20 were effective in oxytocin group, and 10 were ineffective in treatment. The difference between the two groups was significant (P <0.05). Conclusion Xin-Pei for the treatment of uterine atony postpartum hemorrhage in patients with short-term significant increase in uterine strength, reduce the amount of bleeding in patients with significant effect is to save uterine bleeding in maternal mortality select.